Почетна › Сквамозноклеточен карцином на глава и врат › Северна Каролина
Клинички испитувања за Сквамозноклеточен карцином на глава и врат во Северна Каролина
27 студии за Сквамозноклеточен карцином на глава и врат бараат учесници на локации во Северна Каролина.
Градови во Северна Каролина
Официјален текст на студијата (англиски)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site#0118, Durham
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06788990Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #12, Durham
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT05176483Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Margaret R Pardee Memorial Hospital, Hendersonville
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06589804Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07360314A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Carolina Cancer Research Center, Wilson
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of North Carolina at Chapel Hill, Chapel Hill
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06385080BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- Southeastern Medical Oncology Center-Jacksonville, Jacksonville
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05136196JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Levine Cancer Institute, Charlotte
Се регрутираФаза 3
Возраст 60 и постари · Сите полови · Ажурирано 25.9.2026 · NCT04892173A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
- University of North Carolina at Chapel Hill, Chapel Hill
Се регрутираФаза 1
Возраст од 18 до 74 · Сите полови · Ажурирано 25.9.2026 · NCT07219212Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Cone Health Cancer Center, Greensboro
- Annie Penn Memorial Hospital, Reidsville
Се регрутираФаза 2
Возраст од 18 до 79 · Сите полови · Ажурирано 22.9.2026 · NCT04671667Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Carolina Biooncology Institute, Huntersville
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT05267626ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT05059444Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT02734537A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
- Carolina BioOncology Institute /ID# 272380, Huntersville
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT07241039Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT04333537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- и уште 9
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT06532279Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 17.7.2026 · NCT04375384Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Carolina BioOncology Institute, Huntersville
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 23.6.2026 · NCT06993844Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Duke Cancer Institute /ID# 276267, Durham
- Carolina BioOncology Institute /ID# 232597, Huntersville
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 23.6.2026 · NCT05005403Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Duke Cancer Center /ID# 251975, Durham
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 4.6.2026 · NCT04777994Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
- University of North Carolina at Chapel Hill, Chapel Hill
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 28.4.2026 · NCT04564989Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 18.2.2026 · NCT07030257A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Duke Cancer Institute, Durham
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 13.2.2026 · NCT06778863A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Huntersville
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 7.1.2026 · NCT06999187Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- Duke University Medical Center, Durham
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 11.12.2025 · NCT05793151A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2025 · NCT05107674Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Levine Cancer Institute, Charlotte
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 15.8.2025 · NCT04429542Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.